{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:22:11Z","timestamp":1790018531609,"version":"4.0.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003128","name":"Ty\u00f6suojelurahasto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003128","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.cllc.2019.10.013","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T11:52:15Z","timestamp":1572004335000},"page":"e142-e150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4364-2201","authenticated-orcid":false,"given":"Juuso","family":"Paajanen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilkka","family":"Ilonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Lauri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommi","family":"J\u00e4rvinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Sutinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hely","family":"Ollila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eeva","family":"Rouvinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Lemstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jari","family":"R\u00e4s\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Ritvos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katri","family":"Koli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjukka","family":"Myll\u00e4rniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2019.10.013_bib1","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/bjc.2017.22","article-title":"Prognostication and monitoring of mesothelioma using biomarkers: a systematic review","volume":"116","author":"Arnold","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2019.10.013_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 Update of the consensus statement from the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.cllc.2019.10.013_bib3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.chest.2016.12.004","article-title":"Malignant mesothelioma biomarkers \u2013 from discovery to use in clinical practise for diagnosis, monitoring, screening and treatment","volume":"152","author":"Creaney","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.cllc.2019.10.013_bib4","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/153537020623100507","article-title":"Activin signaling and its role in regulation of cell proliferation, apoptosis, and carcinogenesis","volume":"231","author":"Cuen","year":"2006","journal-title":"Exp Biol Med"},{"key":"10.1016\/j.cllc.2019.10.013_bib5","doi-asserted-by":"crossref","first-page":"6954","DOI":"10.1046\/j.1432-1327.2000.01828.x","article-title":"Signaling of transforming growth factor- b family members through Smad proteins","volume":"267","author":"Itoh","year":"2000","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.cllc.2019.10.013_bib6","doi-asserted-by":"crossref","first-page":"32831","DOI":"10.1074\/jbc.M801266200","article-title":"The structure of FSTL3-activin A complex: differential binding of N-terminal domains influences follistatin-type antagonist specificity","volume":"283","author":"Stamler","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.cllc.2019.10.013_bib7","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/carcin\/bgg154","article-title":"Expression of activins C and E induces apoptosis in human and rat hepatoma cells","volume":"24","author":"Vejda","year":"2003","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.cllc.2019.10.013_bib8","doi-asserted-by":"crossref","first-page":"7968","DOI":"10.1158\/0008-5472.CAN-04-3553","article-title":"Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells","volume":"65","author":"Burdette","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.cllc.2019.10.013_bib9","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1593\/neo.81582","article-title":"Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma","volume":"11","author":"Seder","year":"2009","journal-title":"Neoplasia"},{"key":"10.1016\/j.cllc.2019.10.013_bib10","doi-asserted-by":"crossref","first-page":"13388","DOI":"10.18632\/oncotarget.7796","article-title":"High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma","volume":"7","author":"Hoda","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2019.10.013_bib11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.yexcr.2014.12.010","article-title":"Overexpression of activin-A and -B in malignant mesothelioma \u2013 attenuated Smad3 signaling responses and ERK activation promote cell migration and invasive growth","volume":"332","author":"Tamminen","year":"2015","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.cllc.2019.10.013_bib12","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1038\/bjc.2012.519","article-title":"Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells","volume":"107","author":"Hoda","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2019.10.013_bib13","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2016.04.018","article-title":"Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - a multi-institutional study","volume":"63","author":"Hoda","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2019.10.013_bib14","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","article-title":"Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival","volume":"142","author":"Zhou","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.cllc.2019.10.013_bib15","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/jcsm.12209","article-title":"Circulating Activin A predicts survival in cancer patients","volume":"8","author":"Loumaye","year":"2017","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.cllc.2019.10.013_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat3504","article-title":"Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy","volume":"10","author":"Marini","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cllc.2019.10.013_bib17","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2019.10.013_bib18","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2019.10.013_bib19","series-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"10.1016\/j.cllc.2019.10.013_bib20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2018.01.001","article-title":"Computed tomography in the evaluation of malignant pleural mesothelioma\u2014association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival","volume":"116","author":"Paajanen","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2019.10.013_bib21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.21873\/cgp.20005","article-title":"Clinical and therapeutic implications of follistatin in solid tumours","volume":"13","author":"Shi","year":"2016","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.cllc.2019.10.013_bib22","doi-asserted-by":"crossref","first-page":"42189","DOI":"10.18632\/oncotarget.15026","article-title":"Prognostic value of follistatin-like 3 in human invasive breast cancer","volume":"8","author":"Couto","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2019.10.013_bib23","doi-asserted-by":"crossref","first-page":"e111398","DOI":"10.1371\/journal.pone.0111398","article-title":"Follistatin is a novel biomarker for lung adenocarcinoma in humans","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cllc.2019.10.013_bib24","doi-asserted-by":"crossref","first-page":"16239","DOI":"10.1073\/pnas.0705971104","article-title":"Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia","volume":"104","author":"Jones","year":"2007","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.cllc.2019.10.013_bib25","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1530\/eje.0.1480559","article-title":"Serum concentrations of activin and follistatin are elevated and run in parallel in patients with septicemia","volume":"148","author":"Michel","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.cllc.2019.10.013_bib26","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1530\/eje.0.1390487","article-title":"Influence of age and sex on serum concentrations of total dimeric activin A","volume":"139","author":"Loria","year":"1998","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.cllc.2019.10.013_bib27","first-page":"2125","article-title":"Serum immunoreactive activin A levels in normal subjects and patients with various diseases","volume":"81","author":"Harada","year":"1996","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.cllc.2019.10.013_bib28","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejca.2015.12.030","article-title":"Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review","volume":"57","author":"Shachar","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2019.10.013_bib29","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/jcsm.12310","article-title":"Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses","volume":"9","author":"Nissinen","year":"2018","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.cllc.2019.10.013_bib30","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1210\/jc.2014-4318","article-title":"Role of activin a and myostatin in human cancer cachexia","volume":"100","author":"Loumaye","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.cllc.2019.10.013_bib31","first-page":"15","article-title":"Cachexia versus sarcopenia","volume":"14","author":"Rolland","year":"2011","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.cllc.2019.10.013_bib32","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/(SICI)1098-1128(199905)19:3<223::AID-MED3>3.0.CO;2-N","article-title":"The role of cytokines in cancer cachexia","volume":"19","author":"Argil\u00e9s","year":"1999","journal-title":"Med Res Rev"},{"key":"10.1016\/j.cllc.2019.10.013_bib33","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1164\/rccm.201802-0286OC","article-title":"Activin type II receptor blockade for treatment of muscle depletion in COPD: a randomized trial","volume":"199","author":"Polkey","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cllc.2019.10.013_bib34","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/jgs.14927","article-title":"Treatment of sarcopenia with bimagrumab: results from a phase II, randomized, controlled, proof-of-concept study","volume":"65","author":"Rooks","year":"2017","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.cllc.2019.10.013_bib35","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3389\/fphar.2018.00381","article-title":"Commentary: blockade of activin type II receptors with a dual anti-ActRIIA\/IIB antibody is critical to promote maximal skeletal muscle hypertrophy","volume":"9","author":"Dur\u00e1n","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cllc.2019.10.013_bib36","doi-asserted-by":"crossref","first-page":"E41","DOI":"10.1152\/ajpendo.00389.2012","article-title":"Muscle protein synthesis, mTORC1\/MAPK\/Hippo signaling, and capillary density are altered by blocking of myostatin and activins","volume":"304","author":"Hulmi","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.cllc.2019.10.013_bib37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2019.10.013_bib38","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/JTO.0000000000000211","article-title":"Observer variability in mesothelioma tumor thickness measurements: defining minimally measurable lesions","volume":"9","author":"Armato","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.10.013_bib39","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1183\/09031936.00146110","article-title":"Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?","volume":"38","author":"Frauenfelder","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cllc.2019.10.013_bib40","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jtho.2018.02.021","article-title":"Progress in the management of malignant pleural mesothelioma in 2017","volume":"13","author":"Mccambridge","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.10.013_bib41","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2019.10.013_bib42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2007.02.001","article-title":"Mechanisms of resistance to cisplatin and carboplatin","volume":"63","author":"Stewart","year":"2007","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730419302876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730419302876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:10:40Z","timestamp":1761505840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730419302876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1525730419302876"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2019.10.013","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2019.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}